We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Merck KGaA, Darmstadt, Germany, known in the U.S. as EMD Serono, has selected PRA Health Sciences’ remote patient monitoring platform to work in combination with its human growth hormone (HGH) treatment system.
Dublin-based clinical trials group ICON is set to acquire rival contract research organisation (CRO) PRA Health Sciences in a deal worth approximately $12bn.
Symphony Health, PRA Health Sciences’ data solutions division, has expanded its global data services by entering into a strategic partnership with Close-Up International...
The buyout closed June 1. The move will grow PRA’s staff in Japan to 450 “with opportunity for additional growth in the near term,” the CRO said in a statement last week.